Sanderling Ventures Discloses Stake in CalciMedica

TL;DR

**Sanderling Ventures just dropped a 13D on CalciMedica, Inc. Big ownership change incoming.**

AI Summary

On November 26, 2024, Sanderling Venture Partners VI LP and its affiliates filed an SC 13D, reporting beneficial ownership of CalciMedica, Inc. The filing indicates a change in ownership or control, with Sanderling Venture Partners VI LP and its group members now holding a significant stake in the company. The filing details the group members involved in this ownership change.

Why It Matters

This filing signals a potential shift in control or influence over CalciMedica, Inc., which could impact its strategic direction and future operations.

Risk Assessment

Risk Level: medium — SC 13D filings often indicate significant stake acquisitions, which can lead to activist investor involvement or changes in corporate control, introducing uncertainty.

Key Players & Entities

• Sanderling Venture Partners VI LP (company) — Filing entity
• CalciMedica, Inc. (company) — Subject company
• FRED A. MIDDLETON (person) — Group member
• TIMOTHY C. MILLS (person) — Group member
• Sanderling Ventures Management VI (company) — Group member
• Sanderling Ventures Management VII (company) — Group member

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $3.25 — hereof at exercise prices ranging from $3.25 to $4.16. 2 Consists of 2,407,172 sha
• $4.16 — t exercise prices ranging from $3.25 to $4.16. 2 Consists of 2,407,172 shares of co
• $26.74 — n stock at exercise prices ranging from $26.74 to $27.94 per share, (ii) SVP VI Co-Inv
• $27.94 — exercise prices ranging from $26.74 to $27.94 per share, (ii) SVP VI Co-Invest recei
• $5.36 — se common stock at an exercise price of $5.36 per share (the Tranche A Warrants), and
• $7.15 — se common stock at an exercise price of $7.15 per share (the Tranche B Warrants). T
• $3.827 — eement were sold at a purchase price of $3.827 per share of common stock and accompany

Filing Documents

• d865711dsc13d.htm (SC 13D) — 233KB
• d865711dex99a.htm (EX-99.A) — 17KB
• 0001193125-24-265556.txt ( ) — 253KB

From the Filing

SC 13D 1 d865711dsc13d.htm SC 13D SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 CALCIMEDICA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 38942Q 202 (CUSIP Number) Sanderling Venture Partners VI, LP Sanderling Venture Partners VI Co-Investment Fund, L.P. Sanderling Ventures VII, L.P. Sanderling Ventures VII (Canada), L.P. Sanderling Ventures VII Annex Fund, L.P. Sanderling Ventures Management VI Sanderling Ventures Management VII Sanderling VI Beteiligungs GmbH & Co KG Sanderling VI Limited Partnership Fred A. Middleton Timothy C. Mills 1300 S. El Camino Real, Suite 203 San Mateo, CA 94402 (650) 401-2000 with copy to: Evan Ng Dan Lyman Dorsey & Whitney LLP 167 Hamilton Avenue, Suite 200 Palo Alto, CA 94301 (650) 565-2252 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) March 20, 2023 (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 1 NAMES OF REPORTING PERSON: Sanderling Ventures Partners VI, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a)(b) 3 SEC USE ONLY: 4 SOURCE OF FUNDS (SEE INSTRUCTIONS): WC 5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): 6 CITIZENSHIP OR PLACE OF ORGANIZATION: California NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER: 0 8 SHARED VOTING POWER: 968,640 9 SOLE DISPOSITIVE POWER: 0 10 SHARED DISPOSITIVE POWER: 968,640 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 968,640 1 12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): Not Applicable 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 7.1% 2 14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): PN 1 Consists of 946,744 shares of common stock and 21,896 shares of common stock issuable upon the exercise of outstanding warrants received pursuant to the Merger Agreement (as defined below). Does not include 121,678 additional shares of common stock that could be acquired upon exercise of Tranche B Warrants (as defined below) due to the Beneficial 2 The calculation of percentage ownership is based on a total of 13,470,156 shares of common stock outstanding as of November 1, 2024, as set forth in the Issuers prospectus supplement filed with the Securities and Exchange Commission on October 31, 2024. 1 NAMES OF REPORTING PERSON: Sanderling Venture Partners VI Co-Investment Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a)(b) 3 SEC USE ONLY: 4 SOURCE OF FUNDS (SEE INSTRUCTIONS): WC 5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): 6 CITIZENSHIP OR PLACE OF ORGANIZATION: California NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER: 0 8 SHARED VOTING POWER: 838,465 9 SOLE DISPOSITIVE POWER: 0 10 SHARED DISPOSITIVE POWER: 838,465 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 838,465 1 12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 6.2% 2 14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): PN 1 Consists of 814,300 shares of common stock and 24,165 shares of common stock issuable upon the exercise of outstanding warrants received pursuant to the Merger Agreement (as defined below). Does not include 72,338 additional shares of common stock that could be acquired upon exercise of Tranche B Warrants (as defined below) due to the Beneficial 2 The calculation of percentage ownership is based on a total of 13,470,156 shares of common stock outstanding as of November 1, 2024,

View Full Filing

View this SC 13D filing on SEC EDGAR